Citadel Advisors
PGNX

Citadel Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Citadel Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,100
Closed -$67K – 10501
2019
Q4 		$67K Sell
13,100
-39,300
-75% -$208K ﹤0.01% 8681
2019
Q3 		$265K Sell
52,400
-12,600
-19% -$62.8K ﹤0.01% 7750
2019
Q2 		$401K Buy
65,000
+7,100
+12% +$34.2K ﹤0.01% 7147
2019
Q1 		$269K Buy
57,900
+40,300
+229% +$182K ﹤0.01% 7772
2018
Q4 		$74K Sell
17,600
-28,600
-62% -$146K ﹤0.01% 8379
2018
Q3 		$290K Buy
46,200
+5,100
+12% +$39.2K ﹤0.01% 7628
2018
Q2 		$330K Sell
41,100
-9,000
-18% -$68.7K ﹤0.01% 7057
2018
Q1 		$374K Buy
50,100
+22,400
+81% +$149K ﹤0.01% 6379
2017
Q4 		$165K Sell
27,700
-1,600
-5% -$9.72K ﹤0.01% 7231
2017
Q3 		$216K Buy
29,300
+14,600
+99% +$92.7K ﹤0.01% 6576
2017
Q2 		$100K Sell
14,700
-55,000
-79% -$406K ﹤0.01% 6906
2017
Q1 		$658K Buy
69,700
+29,200
+72% +$291K ﹤0.01% 4607
2016
Q4 		$350K Sell
40,500
-7,000
-15% -$51.7K ﹤0.01% 5450
2016
Q3 		$301K Buy
+47,500
New +$287K ﹤0.01% 5668
2016
Q1 		– Sell
-12,400
Closed -$76K – 8514
2015
Q4 		$76K Sell
12,400
-400
-3% -$2.62K ﹤0.01% 6958
2015
Q3 		$73K Sell
12,800
-9,300
-42% -$71.4K ﹤0.01% 7269
2015
Q2 		$165K Buy
22,100
+15,600
+240% +$94.4K ﹤0.01% 6560
2015
Q1 		$39K Sell
6,500
-5,700
-47% -$35.9K ﹤0.01% 7550
2014
Q4 		$92K Buy
12,200
+1,100
+10% +$6.58K ﹤0.01% 6715
2014
Q3 		$58K Buy
11,100
+7,000
+171% +$34.9K ﹤0.01% 6811
2014
Q2 		$18K Sell
4,100
-8,700
-68% -$33.2K ﹤0.01% 7357
2014
Q1 		$52K Buy
12,800
+10,500
+457% +$53.7K ﹤0.01% 6757
2013
Q4 		$12K Sell
2,300
-5,900
-72% -$26K ﹤0.01% 6674
2013
Q3 		$41K Sell
8,200
-600
-7% -$3.25K ﹤0.01% 5900
2013
Q2 		$39K Buy
+8,800
New +$39.5K ﹤0.01% 5791

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Citadel Advisors's PGNX Position: Q2 2020 in Review

Citadel Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 43,193 shares — an estimated $164K sold.

Citadel Advisors first reported a position in PGNX in Q2 2013 and held it in 25 quarters. The position peaked at $10.3M in Q3 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Citadel Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Citadel Advisors sold 43,193 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $164K.
  • Citadel Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 25 quarters.
  • Citadel Advisors's Progenics Pharmaceuticals Inc position peaked at $10.3M in Q3 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.